—
Enter label dose
Trial reference
From your label
Enter your label dose — the gauge updates instantly.
50 mg/day for 4 weeks in a randomized double-blind placebo-controlled crossover trial in Parkinson's disease depression; significant HDRS improvement, no effect on apathy, and the authors call it preliminary. A single small trial in one population, cited by our 5-HTP with SSRIs guide.
Educational only — not medical advice. Disclaimer.
Want the outcome before the arithmetic? The reason check opens any registry entry on this page with its trial result first, then compares your daily intake with the studied amount.
Trial floors
Primary
Depression trial in Parkinson's disease (50 mg/day) · 50 mg over 4 weeks · Significant, low-quality evidence — 50 mg/day for 4 weeks in a randomized double-blind placebo-controlled crossover trial in Parkinson's disease depression; significant HDRS improvement, no effect on apathy, and the authors call it preliminary. A single small trial in one population, cited by our 5-HTP with SSRIs guide. — Funding: not stated in the publication
Other floors
Antidepressant add-on (300 mg/day) · 300 mg over 28 days · Benefit shown — 300 mg/day added to chlorimipramine 50 mg/day in hospitalized depression, double-blind against chlorimipramine plus placebo, for 28 days. Two patients on chlorimipramine plus placebo dropped out. Supervised add-on context only, never a basis for stacking on top of serotonergic medication without a prescriber. — Funding: not stated in the publication
Obesity trial (900 mg/day) · 900 mg over two consecutive 6-wk periods · Significant, low-quality evidence — 900 mg/day in 20 obese adults randomly assigned to 5-HTP or placebo, across two consecutive double-blind 6-week periods. No diet was prescribed during the first period. A 5040-kJ/d diet was recommended for the second. Significant weight loss, lower carbohydrate intake, and earlier satiety were seen on 5-HTP during both periods. The authors report good tolerance. — Funding: not stated in the publication
Safety red flags
- 5-HTP is a direct serotonin precursor. With an SSRI, a human challenge measured a larger prolactin and cortisol response to citalopram. With phenelzine, the published case was mania without clonus. With linezolid, a published letter describes serotonin syndrome. Adding 5-HTP to an SNRI, tramadol, or a triptan belongs in that same prescriber conversation.
Label reading notes
- The floors are two placebo comparisons, one in Parkinson's disease and one in obesity, and one hospital add-on: 300 mg/day with chlorimipramine 50 mg/day. That add-on was given in hospital, under supervision. Putting 5-HTP on an antidepressant by yourself belongs with your prescriber.
- The SSRI pair is graded major in our interaction base. A human challenge found that 200 mg of 5-HTP augmented the prolactin and cortisol response to 20 mg of citalopram. The published phenelzine case was admitted as probable drug-induced mania, and that patient did not have clonus. A published letter describes serotonin syndrome with linezolid, an antibiotic that inhibits monoamine oxidase. An open pilot added 5-HTP plus creatine to an SSRI or an SNRI. No human trial of 5-HTP taken with tramadol or a triptan turned up in the searches behind this page. Any of these combinations belongs with your prescriber.
- Commercial 5-HTP has a published Peak X contaminant family. One 1999 analysis found it in all eight commercial samples tested. A later paper argues that peak is a chromatographic artifact. A third-party test of the batch is a practical check on the bottle. Those seals have not been shown to remove Peak X.